Steven D. Schwartz

A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema

Emmett T. Cunningham, Anthony P. Adamis, Michael M. Altaweel et al. · Ophthalmology · 2005 · 590 citations

Ocular Disease, Ophthalmology, Diabetes +6

Enzymatic transition states and dynamic motion in barrier crossing

Steven D. Schwartz, Vern L. Schramm · Nature Chemical Biology · 2009 · 263 citations · Full text

Cross-link, Protein Folding, Macromolecular Machine +4

Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial

Arshad M. Khanani, Sunil Patel, Giovanni Staurenghi et al. · The Lancet · 2023 · 263 citations · Full text

Clinical Epidemiology, Clinical Trials, Geographic Atrophy +5

Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration

Philip J. Rosenfeld, Steven D. Schwartz, Mark S. Blumenkranz et al. · Ophthalmology · 2005 · 222 citations

Ocular Disease, Angiogenesis, Ophthalmology +7

Progression of Geographic Atrophy in Age-related Macular Degeneration

Tiarnán D L Keenan, Elvira Agrón, Amitha Domalpally et al. · Ophthalmology · 2018 · 201 citations

Ocular Disease, Age-related Diseases, Geographic Atrophy +1